登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07032532,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Patients must have histologically confirmed peripheral T-cell lymphoma. Eligible histological subtypes are restricted to the following:
入选标准第 4 条
Prior treatment with a JAK or STAT3 inhibitor.
排除标准第 6 条
Prior treatment with any onco-immunotherapy in 28 days.
排除标准第 7 条
Patients currently receiving (or unable to stop use at least 14 days prior to receiving the first dose) medications or herbal supplements known to be Potent inhibitors or inducers of CYP3A.
排除标准第 9 条
ECOG performance status 0-2 with no deterioration over the previous 2 weeks.
入选标准第 2 条
Patients must have measurable disease according to the 2014 Lugano classification.
入选标准第 9 条
Another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
排除标准第 15 条
Women who are breast feeding or pregnant.
排除标准第 18 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07032532,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male and female ≥ 18 years old. ECOG performance status 0-2 with no deterioration over the previous 2 weeks. Predicted life expectancy ≥ 12 weeks. Patients must have histologically confirmed peripheral T-cell lymphoma. Eligible histological subtypes are restricted to the following: PTCL, not otherwise specified (PTCL, NOS) (the proportion of PTCL-NOS subtype will not exceed 30% of all enrolled) Angioimmunoblastic T-cell lymphoma (AITL) Follicular T cell lymphoma PTCL with T follicular helper (TFH) phenotype Patients must have measurable disease according to the 2014 Lugano classification. Patients must be treatment naïve with no prior systemic treatment for T-cell lymphoma. Adequate bone marrow reserve and organ system functions. Willing to comply with contraceptive restrictions.排除标准:Exclusion Criteria:
Intervention with any of the following: Any investigational anti-cancer agents or study anti-cancer drugs from a previous clinical study. Any cytotoxic chemotherapy from a previous treatment regimen. Corticosteroids at dosages equivalent to prednisone > 40 mg/day within 7 days. Major surgery procedure, or significant traumatic injury within 4 weeks. Prior treatment with a JAK or STAT3 inhibitor. Prior treatment with any onco-immunotherapy in 28 days. Live vaccines within 28 days. Patients currently receiving (or unable to stop use at least 14 days prior to receiving the first dose) medications or herbal supplements known to be Potent inhibitors or inducers of CYP3A. Central nervous system or leptomeningeal lymphoma. Past medical history of pneumonitis, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease. Patients with disease condition which requires the treatment of immunosuppressants, biologics, or NSAID. Active infections Clinically significant cardiac disorders or abnormalities. Acute thrombotic diseases within 90 days. Another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or nonmelanomatous skin cancer. Gastrointestinal disorders that is inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of golidocitinib. History of hypersensitivity to active or inactive excipients of golidocitinib or drugs with a similar chemical structure or class. Women who are breast feeding or pregnant.
引自 ClinicalTrials.gov, NCT07032532, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07032532,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。